10m agoReutersBEARISH 38General
Why Is CELLDEX THERAPEUTICS (CLDX) Stock Down Today?
By the Top Tier Newswire AI Desk · July 16, 2026 at 9:47 AM ET · reviewed against 9 wire stories
CELLDEX THERAPEUTICS (CLDX) is down -13.42% in the latest session. Our newswire has captured 9 stories on CLDX across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Celldex Therapeutics (CLDX) fell 6.28% to $35.90 in early trading on Monday driven by the filing of an SEC 8-K disclosing the departure or appointment of certain officers. The document highlighted changes in executive compensation arrangements, which has raised questions among investors about leadership stability and strategic direction.
What Happened
The stock opened at $38.07, a modest 0.6% gap down from the prior close, but quickly declined to a session low of $35.67 within 15 minutes of the open. The SEC filing, dated July 15, included details about the departure of directors or certain officers and related compensatory arrangements. While the filing itself does not specify the names of those involved, it is likely linked to the broader context of Celldex's leadership changes. Separately, Benzinga reported that CFO Sam Martin plans to retire in 2027, adding to the narrative of executive transition. The stock closed the session at $35.90 with a volume of 0.1 million shares, which is 0.1 times the 3-month average.
What The Data Shows
Celldex remains unprofitable with a trailing twelve-month (TTM) earnings per share (EPS) of -4.27 and TTM revenue down 88.6%. The stock has traded between $19.72 and $40.30 over the past 52 weeks. Despite recent positive clinical data from its Barzolvolimab and CDX-622 programs, the stock has underperformed in recent weeks, with sentiment trending lower, dropping from a 30-day average of 57/100 to 50/100 over the last seven days. The stock’s beta of 0.90 suggests it is slightly less volatile than the broader market.
What To Watch
Investors should continue to monitor Celldex’s leadership developments and any upcoming corporate actions. The company is scheduled to highlight further data from its clinical programs at the EAACI Annual Congress 2026, which may influence investor sentiment in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CLDX by the numbers
Last: $32.81Session: -13.42%7 sessions: -8.08%Coverage: 9 stories / 8 sourcesAI sentiment: 58/100 (bullish)Mkt cap: $3.0B52w: $19.72 to $40.30
The headlines behind the move
1h agoInvestorsHubBULLISH 73Earnings
Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials
Celldex shares rise 8% as barzolvolimab meets primary and key secondary endpoints in two Phase 3 trials for chronic spontaneous urticaria.
2h agoSeeking AlphaBEARISH 34Product/PR
Celldex falls after late-stage trial data for hives therapy
Celldex (CLDX) stock sank after the company posted Phase 3 trial data for its hives therapy. Read more here.
3h agoInvesting.com MarketsBEARISH 32General
Why is Celldex Therapeutics stock plummeting today?
Why is Celldex Therapeutics stock plummeting today?
3h agoMarketChameleonBULLISH 73Product/PR
Celldex reports Phase 3 barzolvolimab CSU wins as complete response rates approach 54% by Week 24
Celldex reported positive topline Phase 3 results from EMBARQ-CSU1 and EMBARQ-CSU2, with barzolvolimab meeting the primary endpoint and all key secondary endpoints at Week 12. Complete response (UAS7=0) rates were significantly higher than placebo and climbed to as high as 54.00% by Week 24 in EMBARQ-CSU2, while benefits also extended to omalizumab-refractory patients and angioedema resolution. The trials continue to 52 weeks, and Celldex anticipates a BLA submission in 2027.
3h agoInvesting.com MarketsBULLISH 73Product/PR
Celldex stock rises after positive phase 3 trial results
Celldex stock rises after positive phase 3 trial results
4h agoSEC 8-KNEUTRAL 50General
Celldex Therapeutics, Inc. (CLDX) files 8-K
Filed: 2026-09-22 AccNo: 0001104659-26-109465 Size: 245 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
4h agoThe FlyBULLISH 73Product/PR
Celldex’s barzolvolimab meets endpoints in Phase 3 urticaria trial
4h agoStockTitanBULLISH 76Product/PR
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
Frequently asked questions
Why is CLDX stock down today?
CELLDEX THERAPEUTICS (CLDX) is down -13.42% in the latest session. Our newswire has captured 9 stories on CLDX across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100). The most recent driver: "Celldex shares slip as safety concerns cloud skin drug trial win" (Reuters).
Is CLDX a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of CLDX coverage reads 58/100 over 9 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is VKTX up today (+24.91%)
- Why is BFLY up today (+18.37%)
- Why is VICR up today (+12.63%)
- Why is ONON up today (+11.02%)
- Why is CPRI up today (+8.95%)
- Why is LPLA down today (-8.62%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on CLDX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.